Harrow (HROW) EV to CFO (2010 - 2026)
Harrow (HROW) posted EV to CFO of 154.56 for Q2 2026, down 14.0% on a QoQ basis from 135.58 in Q1 2026, and up 88.38% year-over-year from 82.05 in Q2 2025.
Analysis
Harrow (HROW) EV to CFO (2010 - 2026) Analysis & Trends
Harrow has reported EV to CFO for 17 years, with the latest figure at 154.56 in Q2 2026.
- On a quarterly basis, EV to CFO rose 88.38% year-over-year to 154.56 in Q2 2026; TTM through Jun 2026 was 241.16, a 8.84% decrease from a year earlier, with the FY2025 full-year figure at 39.92, up 177.23% from the prior year.
- EV to CFO was 154.56 for Q2 2026 at Harrow, down from 135.58 in the prior quarter.
- The five-year high for EV to CFO was 517.83 in Q3 2024, with the low at 1329.95 in Q2 2025.
- Average EV to CFO over 5 years is 111.9, with a median of 69.33 recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: EV to CFO slumped 696.24% in 2022, then jumped 422.53% in 2025.
- Over 5 years, EV to CFO stood at 91.36 in 2022, then jumped by 139.12% to 35.74 in 2023, then plunged by 280.61% to 64.54 in 2024, then surged by 422.53% to 208.17 in 2025, then slumped by 174.24% to 154.56 in 2026.
- The last three EV to CFO figures came in at 154.56 (Q2 2026), 135.58 (Q1 2026), and 208.17 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 50.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -154.56 |
| Mar 31, 2026 | -135.58 |
| Dec 31, 2025 | 208.17 |
| Sep 30, 2025 | 103.07 |
| Jun 30, 2025 | -1,329.95 |
| Mar 31, 2025 | 44.81 |
| Dec 31, 2024 | -64.54 |
| Sep 30, 2024 | 517.83 |
| Jun 30, 2024 | -243.93 |
| Mar 31, 2024 | -84.65 |
| Dec 31, 2023 | 35.74 |
| Sep 30, 2023 | -356.30 |
| Jun 30, 2023 | 119.68 |
| Mar 31, 2023 | -74.11 |
| Dec 31, 2022 | -91.36 |
| Sep 30, 2022 | -676.37 |
| Jun 30, 2022 | 29.85 |
| Mar 31, 2022 | 137.96 |
| Dec 31, 2021 | -121.75 |
| Sep 30, 2021 | -84.95 |